In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

The role of cardiovascular magnetic resonance imaging in assessing heart failure with a short, contrast-agent free protocol

Session Poster session 1

Speaker Elizabeth Hillier

Congress : EuroCMR 2019

  • Topic : imaging
  • Sub-topic : Cardiac Magnetic Resonance: Myocardium
  • Session type : Poster Session
  • FP Number : P187

Authors : E Hillier (Montreal,CA), M G Friedrich (Montreal,CA)

E Hillier1 , M G Friedrich1 , 1McGill University Health Centre - Montreal - Canada ,

On behalf: MUHC CMR Group

European Heart Journal - Cardiovascular Imaging ( 2019 ) 20 ( Supplement 2 ), ii147

INTRODUCTION: Heart Failure (HF) is the leading cause of cardiovascular morbidity, mortality, and health care use. New technological developments, including the use of T1 and T2-imaging to assess tissue characterization, in Cardiovascular Magnetic Resonance Imaging (CMR) has led to reduced scan times. The potential for contrast-agent free protocols have further been made possible through Oxygenation-Sensitive CMR (OS-CMR) in combination with standardized breathing maneuvers, which has been established as a potential marker for microvascular function.

PURPOSE: The aim of this study was to assess the time of a contrast-free protocol for routine clinical heart failure assessment.

METHODS: Twelve heart failure patients (mean age 64±9 years; 36% female) and fourteen age-matched healthy volunteers (mean age 56±5 years; 64% female) underwent a CMR on a clinical 3T scanner (Skyra, Siemens, Erlangen, Germany). The short, contrast-free CMR protocol included standard cine sequences for ventricular function (short axis stack), T1 mapping (MOLLI, short axis view), T2 mapping (FLASH, short axis view), and OS-CMR (in basal and mid-ventricular short axis views). Strain values were obtained using the standard cine short-axis views and the 2- and 4-chamber long-axis images. The global myocardial oxygenation reserve (MORE) was obtained from OS-CMR images at baseline and during a long breath-hold that was preceded by a 60s period of hyperventilation. Time of scan was determined from the first and last sequences performed.

RESULTS: Compared with the control group, patients with HF had, on average, a higher global T1 (p<0.0001), higher global T2 (p=0.0009), larger end-diastolic volume (p=0.0005), larger end-systolic volume (p<0.0001), larger left-ventricular end-diastolic atrial volume (p=0.0016) and lower left-ventricular ejection fraction (p<0.0001), with a reduced global peak systolic circumferential strain (<0.0001), and global peak systolic longitudinal strain (p<0.0001). In patients, the breathing-induced MORE was also significantly lower than in healthy controls (0.3±3.3 vs 4.5±4.2, p=0.013). The study protocol was significantly shorter (p<0.0001) than the current clinical MRI protocol, 49.3±10.7 and 31.4±8.3 minutes, respectively.

CONCLUSION: A significantly shorter, contrast-free CMR protocol of 31- compared to the standard 49-minute protocol was able to determine that heart failure patients were characterized by functional, mapping, and strain CMR parameters as well as impaired coronary microvascular function, that could be detected by OS-CMR.

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are